Microbia creates carotenoids for food ingredient and nutritional supplement markets

Microbia, Inc., an emerging leader in the production of sustainable specialty ingredients and biomaterials, today announced that it has achieved an important milestone in creating its line of naturally derived carotenoids for the food ingredient and nutritional supplement markets. Utilizing its proprietary metabolic engineering capabilities, the Company has developed microbial strains that produce commercially significant levels of lycopene via fermentation well in excess of five grams per liter. The bright red carotenoid is useful as an antioxidant and traditionally supplied from tomatoes. This achievement clears the way for the initiation of safety studies, and first lycopene sales could occur as early as 2010.

“The results of these studies and the rapid timeline in which they were completed confirm the remarkable potential of our novel bio-manufacturing methods to produce carotenoids, compounds that currently represent a commercial opportunity in excess of $1 billion dollars”

Over the course of the last ten months, Microbia initiated its lycopene program and subsequently demonstrated the ability to produce this carotenoid at high levels in a large scale manufacturing plant.

“The results of these studies and the rapid timeline in which they were completed confirm the remarkable potential of our novel bio-manufacturing methods to produce carotenoids, compounds that currently represent a commercial opportunity in excess of $1 billion dollars,” said Marcus Lovell Smith, Chief Executive Officer of Microbia. “We are already at a substantial cost advantage over many traditional manufacturing processes, and we will continue to aggressively pursue even higher yields and production rates. Moreover, there are over 600 carotenoids found in nature, and we are confident that our technology can be tuned to make any number of them cost effectively.”

With today’s announcement, Microbia has demonstrated its ability to produce multiple carotenoids at a cost competitive industrial scale. The Company is now focused on commercially launching these products.

The carotenoids are part of the Company’s larger effort to develop a unique production platform for lipophilic or “fat-loving” compounds. Microbia researchers have established the feasibility of this platform for producing a wide variety of ingredients, spanning the food, feed and commodity chemical sectors.

http://www.microbia.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Six common flying with food allergies myths